oncology
Medicines

Activated osteoarthritis: a newly reported ICI adverse event

The first report of symptomatic osteoarthritis following immune checkpoint inhibitor (ICI) therapy (post-ICI-aOA) highlights the need for rheumatology input in the management of immune-related adverse events (irAEs) in cancer patients. The report, published in the Journal for ImmunoTherapy of Cancer, comprised 36 patients from the US and Australia treated with an ICI and diagnosed with ...

Already a member?

Login to keep reading.


OR
© 2022 the limbic